Abuse risks and routes of administration of different prescription opioid compounds and formulations.
about
Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United StatesOxymorphone insufflation associated with acute sensorineural hearing loss: case files of the University of Massachusetts medical toxicology fellowship.Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users.Formulation optimization of hot-melt extruded abuse deterrent pellet dosage form utilizing design of experiments.Likeability and abuse liability of commonly prescribed opioids.Extended-release hydrocodone - gift or curse?Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.Measures to quantify the abuse of prescription opioids: a review of data sources and metrics.Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats.Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of OxycodoneThe effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.Nonmedical prescription drug users in private vs. public substance abuse treatment: a cross sectional comparison of demographic and HIV risk behavior profilesAbuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER).An update in options for the treatment of pain: a review of new opioid formulations.Oxycodone for the treatment of postoperative pain.Current topics in opioid therapy for pain management: addressing the problem of abuse.End-of-dose pain in chronic pain: does it vary with the use of different long-acting opioids?Tamper-resistant opioid formulations in the treatment of acute pain.Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial.Long-term efficacy, safety and tolerability of Remoxy for the management of chronic pain.Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.The role of abuse-deterrent formulations in countering opioid misuse and abuse.Patterns of abuse and routes of administration for immediate-release hydrocodone combination products.Opioid abuse-deterrent strategies: role of clinicians in acute pain management.Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.RGS9-2 Modulates Responses to Oxycodone in Pain-Free and Chronic Pain States.Assessing the impact of abuse-deterrent opioids (ADOs): identifying epidemiologic factors related to new entrants with low population exposure.A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphine-Morphine ARER.Prescription Opioids. V. Metabolism and Excretion of Oxymorphone in Urine Following Controlled Single Dose Administration.Drug availability adjustments in population-based studies of prescription opioid abuse.Correlation of Subjective Effects with Systemic Opioid Exposure from Fixed-Dose Combinations of Oxycodone/Acetaminophen in Recreational Users of Prescription Drugs.Using poison center exposure calls to predict prescription opioid abuse and misuse-related emergency department visits.Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid UsersReduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens.Use of strong opioids for chronic pain in osteoarthritis: an insight into the Latin American reality.
P2860
Q28554893-B2CF1340-3FEF-4AAD-B487-B8E8D9F4C897Q30437607-9962C411-E462-4EB8-BB95-4B6FFF2B9F62Q30677208-D521F53E-8ED9-4207-A655-02C220B0E094Q33633597-C0628360-9F79-4956-9011-BFBA6F13F6E0Q33998223-336C0339-F0DA-4FA3-B41A-E320DCA6AF5EQ34300686-1C8C4DA1-6E71-4FD1-A7FA-6BAC619229C1Q34324957-D51C4965-ABCE-4338-97A4-92F9E063686BQ34677759-766C70CC-DD00-42D6-8B9F-8E16A56A68E1Q34808676-38F25518-F586-4161-8770-3617B6A893B6Q35278475-B5B3C9C6-FF8F-48AA-8DED-D8D83A87F455Q36024799-66B91C5E-2C7F-4DD4-9017-8D9AAF6A5224Q36845718-77863864-EB68-4432-A19D-7A32AA6936CAQ36972164-F808559A-16DE-455F-A544-AFD7B4D58F71Q37404465-FD7E932D-5D50-49EE-B361-48BAC4B8C9D4Q37558785-15678C2A-2D12-4DA0-9002-D5FEE98493F4Q37616572-2B61A20C-0678-4911-8840-32EDE49261C9Q37717944-372BED83-B1F5-4E2A-85E8-A3FE09D54F91Q37992491-45A72BB4-10D0-4034-95AD-53FD873CEA9CQ38004077-98A3126A-3365-4928-802A-3C51D7CE667DQ38112360-E13EEF88-065F-42FB-81B3-5543A070C76BQ38174282-92B8EC2D-8A50-45EA-A9BF-60BE8E4EC295Q38187910-15624953-6FCD-45FF-A67D-B0A4E8EBDE41Q38241632-446BC11C-D920-4B2D-A7B4-1FE0AD068A03Q38356233-E6734626-FAF6-4A2A-9F80-7E6F6053CAA5Q38632934-5202110C-FA78-41D9-8644-472CA34899F9Q38643510-FC294F82-E70B-4281-8612-E477EDB051FFQ38644058-2FD398AE-4EE8-446B-9BAB-7EF62D86EE25Q38657470-104C3B46-FEB9-4477-B6E6-D11A9C358E8FQ38707436-B87B4583-FA2B-4055-A968-558DA7883FD8Q38799636-B1606502-5875-4E62-8EE4-34AF3E6BC93FQ39027669-8FC48ED1-7A90-4776-AF13-669E7BAE51B6Q39037700-106BC127-3AFA-49CB-BF59-625C96812C0AQ39368338-6D5678A7-289B-49A0-B444-B51171636633Q39609516-EF56BB1B-8ECF-4D99-B11B-2769E00FB1B6Q40414322-FC3200D9-D597-4281-8C97-BA2339F811D6Q40610091-73A8E4D9-7ECD-4CB6-A31E-827F5CAA8C45Q42244056-0AC7646B-BD8C-4B4A-B756-580412C8AC62Q42357273-3CF7D149-F0B5-4BCC-A532-C57D23B52881Q42954843-A06BC59D-C230-496B-9869-5559434519DFQ43076011-A024E284-5CE4-4DDA-8A5E-F836CCA0C341
P2860
Abuse risks and routes of administration of different prescription opioid compounds and formulations.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Abuse risks and routes of admi ...... id compounds and formulations.
@ast
Abuse risks and routes of admi ...... id compounds and formulations.
@en
type
label
Abuse risks and routes of admi ...... id compounds and formulations.
@ast
Abuse risks and routes of admi ...... id compounds and formulations.
@en
prefLabel
Abuse risks and routes of admi ...... id compounds and formulations.
@ast
Abuse risks and routes of admi ...... id compounds and formulations.
@en
P2093
P2860
P356
P1476
Abuse risks and routes of admi ...... id compounds and formulations.
@en
P2093
Ryan A Black
Simon H Budman
Taryn M Dailey
Theresa A Cassidy
P2860
P2888
P356
10.1186/1477-7517-8-29
P577
2011-10-19T00:00:00Z
P5875
P6179
1048648370